Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 4/20 | 0.43 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19219764 | 0.91 | ACLY (0.44) | ACLYCYP11B2TRIM24P2RY4XIAP | |
| SCHEMBL17545073 | 0.88 | CYP11B2 (0.52) | ACLYCYP11B2TRIM24CYP11B1ACHE | |
| SCHEMBL17545354 | 0.86 | ACLY (0.61) | ACLYTRIM24P2RY4HPGDKMT2A | |
| SCHEMBL17545337 | 0.83 | ACLY (0.60) | ACLYTRIM24P2RY4XIAPBIRC2 | |
| SCHEMBL17545147 | 0.80 | ACLY (0.54) | ACLYTRIM24P2RY4XIAPBIRC2 | |
| SCHEMBL29707979 | 0.79 | ACLY (0.61) | ACLYTRIM24P2RY4XIAPBIRC2 | |
| SCHEMBL10598052 | 0.79 | XIAP (0.60) | ACLYTRIM24P2RY4XIAPBIRC2 | |
| SCHEMBL15882300 | 0.79 | ACLY (0.61) | ACLYTRIM24P2RY4XIAPBIRC2 | |
| SCHEMBL19219757 | 0.79 | CYP11B2 (0.41) | CYP11B2P2RY4ACHEHTR2AHTR2C | |
| SCHEMBL17545250 | 0.78 | ACLY (0.58) | ACLYTRIM24P2RY4XIAPBIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180312-B1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | UNIV LOYOLA CHICAGO (US) | 2019-10-16 | — | — | EP | disclosed |
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-08-10 | — | — | US | disclosed |
| WO-2016025637-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | LOYOLA UNIVERSITY OF CHICAGO (US) | 2016-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226090-A1 | INDOLINE SULFONAMIDE INHIBITORS OF DAPE AND NDM-1 AND USE OF THE SAME | INMT, MGAM, NNMT | ACLY 1668/4885CYP11B2 3486/4885TRIM24 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.